Publications by authors named "R Zeppa"
Article Synopsis
- * Standard treatments include palliative chemotherapy and radiotherapy, with platinum-based doublets combined with third-generation agents as the first-line therapy; histology plays a key role in treatment decisions.
- * Advances in targeted therapies have identified key molecular targets like VEGF and EGFR, leading to the development of treatments such as bevacizumab and gefitinib that have shown improved survival rates in certain patient populations.
Non-small-cell lung cancer (NSCLC) is not considered to be immunogenic, but it may provide an accessible target for the properly primed immune system. Identifying lung tumor antigens and presenting them in the optimal context may enable the immune system to generate anti-lung tumor effector cells, which are usually absent. Despite encouraging preclinical and Phase I-II data, no specific active cancer vaccine has been approved for NSCLC therapy to date.
View Article and Find Full Text PDFArticle Synopsis
- Lung cancer remains the top cause of cancer-related deaths globally, particularly affecting older adults who are increasingly being considered for chemotherapy.
- Assessing elderly patients’ overall health through a comprehensive geriatric assessment is crucial to determine the best chemotherapy approach since some can handle it well while others may need adjustments due to severe side effects.
- There is a lack of focused clinical trials for older patients with advanced non-small cell lung cancer (NSCLC), and future research should prioritize including evaluations of functional status and comorbidities for better treatment outcomes.
Human leukemia results from multiple mutations that lead to abnormalities in the expressions and functions of genes that maintain the delicate balance between proliferation, differentiation and apoptosis. Continued research on the molecular aspects of leukemia cells has resulted in the developments of several potentially useful therapeutic agents. Discovery of new cellular and/or molecular pathways enabling innate or acquired resistance of cancers to current chemotherapeutics to be overcome is therefore of crucial importance if one wants to efficiently combat those cancers associated with dismal prognoses.
View Article and Find Full Text PDF